Melodiol Global Health

Melodiol Global Health: Global Portfolio of Strategic Cannabis and Plant-based Businesses


Melodiol Global Health (ASX:ME1, FRA:1X8) is a significant player in the global cannabis market with a value proposition founded on its strategic operations in both Canada and Australia.

Melodiol oversees multiple global business units that provide everything from recreational and medical cannabis to hemp-based, athletic, beauty and personal care products. Through subsidiary Halucenex Life Sciences, the company has also dipped its toes into the medical psychedelics market.

Melodiol Global Business Units

Melodiol's two most significant subsidiaries, by far, are Mernova and Health House International. The former is a licensed Canadian producer of small-batch, high-quality craft cannabis with incredibly strong revenue growth. The former is a leading distributor of medical cannabis in Australia with additional non-cannabis operations in the United Kingdom.

Mernova is a 100-percent-owned subsidiary of Melodiol which produces high-quality craft cannabis for recreational use. Its products are among the most concentrated in the Canadian market, with THC content typically 25 percent or higher and are currently available in Saskatchewan, Ontario, Nova Scotia, New Brunswick, Manitoba, Yukon and Newfoundland. Mernova is notable as the first of Melodiol's divisions to generate positive cash flow from operations, achieving significant revenue growth in the first half of 2023. The company currently aims to bring its Mernova products to other markets within Canada and has recently launched a medicinal cannabis division.

Company Highlights

  • A significant player in the global cannabis market, Melodiol Global Health is well-positioned to capitalise on a global trend toward recreational and medical cannabis legalization.
  • Melodiol has built a diverse portfolio of plant-based brands situated in multiple high-growth market segments and geographies:
    • Mernova, a licensed producer of craft cannabis products in Canada sold under the Ritual brand banner.
    • Health House International is a leading Australian distributor of medicinal cannabis.
    • Sierra Sage Herbs is an American developer of plant-based first aid, beauty and personal care brands Green Goo, Southern Butter and Good Goo.
    • Creso ImpACTIVE, which produces high quality hemp-derived CBD products for athletes.
    • Halucenex, a clinical-stage psychedelics research and development operation.
    • Creso Pharma Switzerland, which carries out CBD-related research, development and commercialization initiatives.
  • Melodiol has displayed incredibly strong financial performance throughout 2023, with significant revenue growth and notable improvements in core business unit EBITDA margins.
  • The company intends to continue on its current path of generating value for shareholders through strong operational and financial performance.

This Melodiol Global Health profile is part of a paid investor education campaign.*

Click here to connect with Melodiol Global Health (ASX:ME1, FRA:1X8) to receive an Investor Presentation

ME1:AU
The Conversation (0)
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×